Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy.
We assessed the clinical variables predicting the feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy. Thirty patients aged 15 years or older with refractory partial epilepsy, who had been treated with slow-release carbamazepine as monotherapy or in combination therapy, were switched overnight from slow-release carbamazepine (mean dose at switching, 900 mg/day) to oxcarbazepine. Of these 30 patients, 29 (96.7%) had been treated with a slow-release formulation of carbamazepine. The proportion of patients with polytherapy was 85.3%. Overall, 9 of 30 (30%) switched patients experienced clinically significant adverse events until 2 weeks after switching, including 2 with seizure aggravation. The only clinical variable related to the failure of overnight switching was the number of seizures at baseline.
Lee
Sang-Ahm
SA
Department of Neurology, University of Ulsan, Seoul, Republic of Korea.
Heo
Kyoung
K
Kim
Won-Joo
WJ
Song
Hong-Ki
HK
Kim
Sung-Eun
SE
Kim
Sang-Ho
SH
No
Soon-Kee
SK
Lee
Byung-In
BI
D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004351:Drug Resistance; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D005544:Forecasting; D006801:Humans; D007723:Korea; D008297:Male; D000078330:Oxcarbazepine; D012640:Seizures / Q000453:epidemiology / Q000517:prevention & control; D017211:Treatment Failure
D000927:Anticonvulsants; D003692:Delayed-Action Preparations; D002220:Carbamazepine; D000078330:Oxcarbazepine